PolyPid Ltd
NASDAQ:PYPD
Intrinsic Value
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PYPD.
PolyPid Ltd's market capitalization is 21.5m USD.
PYPD stock price is 4.4845 USD.
PYPD.
PYPD. Open DCF Valuation
PYPD. Open Relative Valuation
PYPD has upside potential of 181% compared to the average analyst price target.
Open Wall St Estimates
PYPD has negative Free Cash Flow for the last twelve months.
PYPD has positive Net Debt. This means that the company has more debt (6m USD) than cash and short-term investments (5m USD).
PYPD's long-term liabilties (17m USD) exceed its long-term assets (15m USD).
PYPD's short-term liabilties (7m USD) exceed its short-term assets (6m USD).
PYPD has negative Operating Income for the last twelve months.
PYPD has negative Net Income for the last twelve months.
PYPD's ROE (Return on Equity) has significantly decreased in the last 3 years from -106% to -1 278%, and is approaching profitability.
PYPD's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -237% to -213%, and is approaching profitability.
PYPD's ROE (Return on Equity) for the past 12 months is negative and is equal to -1 278%.
PYPD's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -213%.
PYPD has negative three-year average ROE (Return on Equity): -231%. The company is not efficient at transforming stockholders' equity into net income.
PYPD has negative three-year average ROIC (Return on Invested Capital): -290%. The company is not efficient at using invested capital to generate operating income.
PYPD's D/E (Debt to Equity) is very low and is equal to -3.04.
PYPD's Altman Z-Score is very low and is equal to -26.5.
PYPD doesn't generate enough operating income (-23m USD) to safely cover interest payments on its debt (490k USD).
Fundamental Analysis
PolyPid Ltd
Balance Sheet Decomposition
PolyPid Ltd
| Current Assets | 6.1m |
| Cash & Short-Term Investments | 5.3m |
| Other Current Assets | 758k |
| Non-Current Assets | 9.3m |
| PP&E | 9.2m |
| Other Non-Current Assets | 87k |
| Current Liabilities | 7.3m |
| Accounts Payable | 772k |
| Accrued Liabilities | 2.5m |
| Other Current Liabilities | 4m |
| Non-Current Liabilities | 10.2m |
| Long-Term Debt | 6.4m |
| Other Non-Current Liabilities | 3.8m |
Earnings Waterfall
PolyPid Ltd
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-22.9m
USD
|
|
Operating Income
|
-22.9m
USD
|
|
Other Expenses
|
-998k
USD
|
|
Net Income
|
-23.9m
USD
|
Free Cash Flow Analysis
PolyPid Ltd
PYPD Profitability Score
Profitability Due Diligence
PolyPid Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
PolyPid Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
PYPD Solvency Score
Solvency Due Diligence
PolyPid Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
PolyPid Ltd's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYPD Price Targets Summary
PolyPid Ltd
According to Wall Street analysts, the average 1-year price target for
PYPD
is 12.58 USD
with a low forecast of 10.1 USD and a high forecast of 14.7 USD.
Shareholder Return
PYPD Price
PolyPid Ltd
| Average Annual Return | -58.11% |
| Standard Deviation of Annual Returns | 25.83% |
| Max Drawdown | -99% |
| Market Capitalization | 21.5m USD |
| Shares Outstanding | 4 797 250 |
| Percentage of Shares Shorted | 0.09% |
Company Profile
PolyPid Ltd
Country
Industry
Market Cap
Dividend Yield
Description
PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
You don't have any saved screeners yet
